Last November and then again in February, Bristol Myers Squibb said its oral drug designed to treat psoriasis differently from currently approved medicines had achieved the goals of large Phase 3 clinical trials.<\/p>\n
On Friday, the actual data from those two studies were presented publicly for the first time at the annual meeting of the American Academy of Dermatology. The Bristol drug, called deucravacitinib, proved more effective at clearing the chronic skin disease numerically and statistically compared to a placebo and a competing drug from Amgen.<\/p>\n
Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!<\/p>\n
STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis.Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.<\/p>\n
<\/p>\n
Read the original: Last November and then again in February, Bristol Myers Squibb said its oral drug designed to treat psoriasis differently from currently approved medicines had achieved the goals of large Phase 3 clinical trials. Continue reading
\nNew data point to benefits of Bristol's novel psoriasis pill, but safety issues will be scrutinized - STAT<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"